This CME/CEU activity is designed to give clinicians a better understanding of the pharmacology, indications, contraindications, benefits/risk and clinical trials data of a broad spectrum of new agents and those that have been granted a new indication.
Tofacitinib plus MTX was shown to be non-inferiority vs. adalimumab plus MTX, however, Xeljanz monotherapy did not meet its primary endpoint for non-inferiority vs.adalimumab plus MTX, or vs. Xeljanz plus MTX.
Pfizer announced that the FDA has approved a sNDA to update the current label of Xeljanz (tofacitinib citrate) tablets to include radiographic data from two Phase 3 studies, ORAL Scan and ORAL Start.
Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.
Patients treated with JAK inhibitors for rheumatoid arthritis may be less likely to have low disease activity if they are obese compared with those who are overweight.
Among a new line of biological and targeted synthetic DMARD, ustekinumab and secukinumab have shown favorable safety and efficacy profiles for psoriasis and arthritis, respectively in patients with psoriatic arthritis.
Pfizer announced that the FDA has approved Xeljanz (tofacitinib citrate) tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had inadequate response or intolerance to methotrexate.
Vaccination rates in patients with rheumatoid arthritis remain poor "despite the high rates of infectious disease-related morbidity and mortality," a review published in Clinical Opinion in Rheumatology has found.
The researchers concluded their findings indicate that for patients with RA, abatacept reduced the risk for diabetes and "potentially improved insulin sensitivity and glycemic profile."
A reduction in risk for cardiovascular disease has been reported among patients with rheumatoid arthritis who are receiving concomitant therapy with methotrexate and biologic disease-modifying antirheumatic drugs.
